MAP2K7 and lung carcinoma: In BRAF wild-type lung cancer preclinical models, the biological active properties of single or combined therapies for BRAF (dabrafenib), pan-RAF (RAF265), MEK (trametinib), and EGFR/HER2 (lapatinib) were evaluated.